Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Shares Issued: 2019-2025

Historic Shares Issued for Nurix Therapeutics (NRIX) over the last 2 years, with Aug 2025 value amounting to $977,000.

  • Nurix Therapeutics' Shares Issued fell 97.67% to $977,000 in Q3 2025 from the same period last year, while for Aug 2025 it was $137.8 million, marking a year-over-year increase of 48.93%. This contributed to the annual value of $289.8 million for FY2024, which is 12899.69% up from last year.
  • Per Nurix Therapeutics' latest filing, its Shares Issued stood at $977,000 for Q3 2025, which was down 21.96% from $1.3 million recorded in Q1 2025.
  • Over the past 5 years, Nurix Therapeutics' Shares Issued peaked at $93.6 million during Q4 2024, and registered a low of -$183,000 during Q4 2022.
  • Over the past 3 years, Nurix Therapeutics' median Shares Issued value was $1.4 million (recorded in 2023), while the average stood at $23.7 million.
  • Per our database at Business Quant, Nurix Therapeutics' Shares Issued plummeted by 133.08% in 2021 and then skyrocketed by 5,312.37% in 2024.
  • Over the past 5 years, Nurix Therapeutics' Shares Issued (Quarterly) stood at -$43,000 in 2021, then climbed by 2.01% to -$183,000 in 2022, then skyrocketed by 36.56% to $776,000 in 2023, then skyrocketed by 5,312.37% to $93.6 million in 2024, then tumbled by 97.67% to $977,000 in 2025.
  • Its Shares Issued was $977,000 in Q3 2025, compared to $1.3 million in Q1 2025 and $93.6 million in Q4 2024.